Physician profile
Michael A Satryan
NPI 1265490593
$4,331.67
in general payments reported to CMS, 2019-2025
14 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $267 · 2021: $452 · 2022: $1,794 · 2023: $973 · 2024: $159 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,667.83 | 2019-2025 | Precision 1, Dailies Total1, Precision7 |
| Coopervision INC. | $348.49 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $305.89 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Johnson & Johnson Vision Care, INC. | $204.53 | 2019-2023 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.96 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $123.02 | 2019-2023 | Cequa |
| Kala Pharmaceuticals, INC. | $108.89 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $108.43 | 2020-2023 | |
| Topcon Healthcare, INC. | $104.47 | 2023 | |
| Lkc Technologies, INC. | $94.70 | 2023 | |
| Optovue, INC. | $55.46 | 2019 | |
| Oyster Point Pharma, INC. | $37.98 | 2022-2024 | Tyrvaya |
| Shire North American Group INC | $30.32 | 2019 | |
| Maculogix, INC. | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Satryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.